Antimalarial Drug Artemotil Shows Promise Against Cartilage Scarring in Osteoarthritis

An old malaria drug is stealing the spotlight in one of medicine’s most stubborn battles. Artemotil, a semisynthetic derivative of the antimalarial compound artemisinin, has been shown to slow the fibrotic scarring that quietly destroys cartilage in osteoarthritis, according to a new study published in the Journal of Cellular and Molecular Medicine. The research, led by a team at Ningxia Medical University in China, suggests the drug works by suppressing a little-known signalling molecule called stanniocalcin-1, or STC1, which appears to drive chondrocytes — the sole cell type of cartilage — into a fibrosis-like identity shift. With no disease-modifying osteoarthritis drug currently approved anywhere in the world, the finding offers a genuinely new angle: instead of merely dampening inflammation or blocking matrix-degrading enzymes, Artemotil appears to intercept the cellular reprogramming that turns smooth, weight-bearing hyaline cartilage into stiff, scar-like fibrocartilage.

Osteoarthritis is usually described as a wear-and-tear disease, but beneath the joint surface a more sinister transformation takes place. Healthy articular cartilage owes its remarkable mechanical properties to collagen type II, encoded by the COL2A1 gene, which forms a resilient, water-rich lattice perfectly suited to absorbing decades of load. In osteoarthritic joints, that lattice is progressively replaced by collagen type I — the fibre-forming protein of scars, tendons and bone — encoded by COL1A1. The result is a tissue that is harder, stiffer and far less able to distribute stress, a transition researchers now recognise as cartilage fibrosis. This phenotypic drift has emerged as a critical, and previously underexplored, driver of disease progression, distinct from the better-known catabolic breakdown mediated by enzymes such as matrix metalloproteinases MMP-3 and MMP-13 and the aggrecan-cleaving ADAMTS4 and ADAMTS5.

The investigative team began with a hunch drawn from artemisinin’s expanding résumé. Originally isolated from sweet wormwood and famously recognised with the 2015 Nobel Prize, artemisinin derivatives have accumulated evidence of anti-fibrotic activity in the kidney, liver and heart. Artemotil, also known as beta-arteether, is a more lipophilic semisynthetic analogue, a property that can alter tissue distribution and biological behaviour. To test whether the compound could influence cartilage fibrosis, the researchers first established an inflammatory model in primary mouse chondrocytes by exposing the cells to interleukin-1 beta, a potent pro-inflammatory cytokine abundant in osteoarthritic joints. IL-1 beta triggered the expected damage signature: COL2A1 plummeted, COL1A1 surged, and the catabolic enzymes MMP-3, MMP-13, ADAMTS4 and ADAMTS5 all rose. Treatment with 10 micromolar Artemotil significantly blunted each of these changes, and immunofluorescence microscopy confirmed the shift visually — collagen II signals recovered while collagen I signals receded. Critically, a cell viability screen showed no toxicity at this concentration over 24 hours.

The in vivo results were more striking. Using the destabilisation of the medial meniscus (DMM) model — the gold-standard surgical model in which transection of a knee ligament induces progressive osteoarthritis — mice received daily intraperitoneal injections of Artemotil at 25 or 50 milligrams per kilogram for four or eight weeks. Histological scoring on the OARSI scale revealed significantly less cartilage degeneration in treated animals, and micro-computed tomography showed smaller and fewer osteophytes, the bony spurs that frill arthritic joint margins. The drug also tempered the erratic remodelling of the subchondral bone plate beneath the cartilage, preventing both the early loss of bone volume fraction and tissue mineral density at four weeks and the later sclerotic hardening at eight weeks. Immunofluorescence of the joint tissue told the molecular story: collagen I staining that flared up in untreated osteoarthritic cartilage was markedly reduced by Artemotil, while collagen II, the hallmark of hyaline cartilage, was preserved.

To find the molecular culprit the drug was reining in, the team turned to quantitative proteomics. Using a timsTOF Pro mass spectrometer with dia-PASEF acquisition and DIA-NN software processing at a 1 percent false discovery rate, they compared protein expression across control, IL-1 beta-stimulated, and Artemotil-treated chondrocytic cells. One protein stood out: STC1 rose with inflammatory stimulation and fell with drug treatment. Stanniocalcin-1, first discovered as a calcium-regulating hormone in fish, has since been implicated in tissue remodelling, cellular stress responses and fibrosis-associated signalling in multiple organs — but its role in cartilage had never been clearly defined. The team validated the finding at every level available: quantitative PCR and Western blotting confirmed the mRNA and protein changes in primary chondrocytes, and the public GEO dataset GSE75181 independently showed STC1 upregulation in human osteoarthritic cartilage compared with non-diseased samples.

The human evidence may prove the most compelling part of the study. Working with cartilage samples from eight patients undergoing total knee replacement, the researchers took paired biopsies from the same knee — the heavily damaged, weight-bearing medial tibial plateau and the relatively spared lateral plateau. Immunofluorescence showed significantly stronger STC1 staining in the diseased medial cartilage of every pairing, effectively using each patient as their own control and ruling out systemic confounders. In the mouse DMM joints, the pattern held: STC1 climbed with disease and dropped with Artemotil. Gene set enrichment analysis centred on STC1 pointed toward inflammatory, immune and extracellular-matrix gene programmes, and notably toward transforming growth factor beta-related pathways, handing the team their next experimental thread.

That thread led to the SMAD proteins, the canonical intracellular messengers of TGF-beta signalling. Western blotting and immunofluorescence revealed that IL-1 beta boosted C-terminal phosphorylation of SMAD2/3 — the activating modification that sends these proteins into the nucleus to rewire gene expression — while Artemotil treatment suppressed it, both in cultured chondrocytes and in mouse cartilage. Total SMAD2/3 levels stayed flat, indicating a change in signalling activity rather than protein abundance. Intriguingly, phosphorylation of the parallel SMAD1/5 branch, often linked to catabolic and hypertrophic responses, showed no significant change, suggesting the drug’s effect is comparatively selective. When the researchers forced STC1 overexpression in chondrocytic SW1353 cells using lentiviral vectors, the fibrotic programme roared back even in the presence of Artemotil: collagen I, ADAMTS5 and MMP-3 climbed, collagen II fell, and p-SMAD2/3 rose. Conversely, blocking the TGF-beta receptor with the inhibitor SB-431542 in STC1-overexpressing cells reversed the fibrotic marker profile, functionally placing STC1 upstream of or alongside TGF-beta-responsive SMAD2/3 signalling.

The authors are refreshingly candid about what the data do and do not prove. The proteomic screen was performed in a cell line, and STC1 was probed only by gain-of-function; loss-of-function experiments and targeted in vivo modulation remain to be done. The measured p-SMAD2/3 is a biochemical readout that does not capture SMAD2/3 linker phosphorylation or the ALK1-to-ALK5 receptor balance, both of which can flip the biological meaning of TGF-beta signalling in cartilage from protective to destructive. Molecular docking and dynamics simulations suggested only a theoretical structural compatibility between Artemotil and STC1, not direct binding, and the drop in STC1 mRNA hints the drug may act at the transcriptional level instead. The animal studies pooled male and female mice without the statistical power to detect sex-specific responses, and no formal a priori power calculation was performed. Systemic safety was assessed only by liver histology in the short term.

Even with those caveats, the convergence of evidence is hard to ignore. A single approved-origin compound, already used clinically as an antimalarial, preserved hyaline cartilage matrix, curbed osteophyte formation, stabilised subchondral bone and dialled down a fibrosis-associated signalling axis — with validation stretching from mass spectrometry data through mouse joints to human surgical specimens. The researchers themselves flag that intra-articular delivery, rather than the systemic injections used here, could concentrate the drug in the joint while limiting systemic exposure, a question for future pharmacokinetic work. If follow-up studies confirm causality and establish safety, the odd couple of a Nobel-winning malaria molecule and a fish hormone could open one of the most credible new front doors yet into disease-modifying osteoarthritis therapy — a field that has, until now, been waiting at a locked one.

Subject of Research: Fibrosis-associated chondrocyte remodelling and STC1-related TGF-beta/SMAD2/3 signalling in osteoarthritis

Article Title: Artemotil Attenuates Fibrosis‐Associated Chondrocyte Remodelling in Osteoarthritis in Association With STC1‐Related TGF‐β/SMAD2/3 Signalling

Article References: Zhu, G., Yang, Y., Ma, Y., Wu, G., Tian, K., He, X., Wang, R., Ma, P., Tang, Z., & Jin, Q. (2026). Artemotil Attenuates Fibrosis‐Associated Chondrocyte Remodelling in Osteoarthritis in Association With STC1 ‐Related TGF ‐β/ SMAD2 /3 Signalling. Journal of Cellular and Molecular Medicine, 30(18), Article e71374. https://doi.org/10.1111/jcmm.71374

Image Credits: AI Generated

DOI: 10.1111/jcmm.71374

Keywords: osteoarthritis, Artemotil, artemisinin, cartilage fibrosis, chondrocytes, STC1, TGF-beta, SMAD2/3, COL2A1, COL1A1, DMM mouse model, proteomics